CLINICAL NEWS
Written in
Featured research from recent issues of Blood
PAPER SPOTLIGHT
Early-Phase Study of Selinexor With and
Without Dexamethasone for Patients With
Myeloma and Waldenström Macroglobulinemia
According to results of a phase I study
published in Blood, treatment with the XPO1
inhibitor selinexor and dexamethasone led to
half of patients with heavily pretreated my-
eloma responding and 46 percent of patients
showing a reduction in myeloma markers
from baseline. However, the results with se-
linexor alone were more modest, with just 4
percent of patients responding to treatment.
The small study, led by Christine Chen,
MEd, MD, from the Princess Margaret Cancer
Centre in Toronto, Ontario, assessed the
safety, efficacy, and recommended maximum
tolerated dose (MTD) of selinexor with or
without dexamethasone in adult patients
with relapsed/refractory myeloma (n=81)
or Waldenström macroglobulinemia (WM;
n=3). This was conducted as part of a larger,
multicenter, dose-escalation, phase I study
assessing selinexor in pati